#USA #New York #Class Action #Shareholders #Intellia Therapeutics

Class Action Lawsuit Notification for Intellia Therapeutics Shareholders

The Gross Law Firm has officially notified shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA) regarding a class action lawsuit as well as an important deadline for participation. Investors who purchased shares of NTLA during the specified class period are urged to get in touch with the law firm to discuss their options. Participation in the lawsuit does not necessitate a lead plaintiff appointment.

Key Highlights from the Lawsuit Notification

The class period for the lawsuit is outlined between July 30, 2024, and January 8, 2025. During this time, shareholders may have been impacted by critical developments within Intellia Therapeutics related to their drug candidate NTLA-3001, which is aimed at treating alpha-1 antitrypsin deficiency (AATD)-associated lung disease.

The complaint alleges that the statements made by the company officials regarding the study of NTLA-3001 were misleading. Initially, there was a strong belief that patient dosing would commence by the second half of 2024. However, it later became apparent that the demand for viral-based editing methods was declining, as non-viral delivery techniques gained traction due to their cost-effectiveness and efficiency. This situation put Intellia's NTLA-3001 program under scrutiny, suggesting it may not be viable moving forward.

On January 9, 2025, the truth surrounding the situation was revealed when Intellia released a press statement announcing a major company restructuring. It confirmed that all research and studies related to NTLA-3001 would be halted, and a reduction in workforce by 27% was set to occur in 2025. The company decided to redirect its resources toward other areas of pharmaceutical development.

Impact on Share Price

Following the announcement, Intellia's stock experienced a dramatic decline, dropping from a closing market price of $12.02 per share on January 8, 2025, to $10.20 per share just two days later. This significant loss has raised concern among investors and highlighted the importance of the upcoming legal proceedings.

Important Dates and Steps for Shareholders

Shareholders are reminded that the deadline to register for the class action lawsuit is April 14, 2025. For those who bought shares of NTLA during the class period, it is crucial to sign up promptly to ensure they are informed about the developments in the case. Upon registration, shareholders will receive status updates as the legal process unfolds.

About The Gross Law Firm

The Gross Law Firm is recognized nationally for representing investors against fraudulent and illegal business practices. Their mission focuses on holding companies accountable and recovering losses for investors who have been misled by false statements or critical omissions of information leading to inflated stock prices.

If you are an Intellia Therapeutics shareholder and have experienced losses due to recent events, reaching out to The Gross Law Firm may be a vital step in seeking potential recovery. As with all legal matters, participation comes at no cost or obligation.

For further information or assistance, contact The Gross Law Firm at 15 West 38th Street, 12th floor, New York, NY, 10018, via email at [email protected], or by phone at (646) 453-8903.